BackHemab Therapeutics Holdings Common Stock Overview

Hemab Therapeutics Holdings Common Stock Receivables

Track Hemab Therapeutics Holdings Common Stock's receivables ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$0.00

Peer trimmed avg / median

Loading

Hemab Therapeutics Holdings Common Stock Receivables History

Loading

Hemab Therapeutics Holdings Common Stock vs. peers: Receivables Comparison

Loading

Hemab Therapeutics Holdings Common Stock Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Hemab Therapeutics Holdings Common Stock (COAG) FAQ

As of the most recent data (June 2026), COAG shows a receivables of $0. Scroll down for historical charts and peer comparison views.

Tracking COAG's receivables over time shows whether Hemab Therapeutics Holdings Common Stock is scaling, shrinking, or reshaping that part of the business. The current reading is $0 Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Hemab Therapeutics Holdings Common Stock's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $0) with ownership activity and broader fundamentals.

Hemab Therapeutics Holdings Common Stock's receivables is $0; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.